Market access: evolving commercialization trends and strategies

CELL AND GENE THERAPY INSIGHTS

Market access: evolving commercialization trends and strategies

August 2020
Market access: evolving commercialization trends and strategies
Download PDF

Foreword

Under construction: roadmaps for HTA, pricing and reimbursement of cell and gene therapies

Under construction: roadmaps for HTA, pricing and reimbursement of cell and gene therapies

Neil Palmer
3 September 2020
Read

Expert Insight

Challenges and proposed solutions to value assessment and reimbursement of CAR-T therapies in Europe

Challenges and proposed solutions to value assessment and reimbursement of CAR-T therapies in Europe

Martin Price
28 August 2020
Read

Commentary

The heart of market access: opportunities and challenges for cell and gene therapy development for orphan and prevalent cardiovascular diseases

The heart of market access: opportunities and challenges for cell and gene therapy development for orphan and prevalent cardiovascular diseases

Faraz Ali
23 September 2020
Read
Joint collaborations and future perspectives for gene therapies.

Joint collaborations and future perspectives for gene therapies.

M Dabbous, B Borissov, C Dussart et al.
3 September 2020
Read
Bringing advanced therapies to the clinic: the Swedish National ATMP Consortium (CAMP/SWElife ATMP)

Bringing advanced therapies to the clinic: the Swedish National ATMP Consortium (CAMP/SWElife ATMP)

Stefan Scheding, Heather Main, Pontus Blomberg
18 August 2020
Read
Challenges in the adoption of regenerative medicine therapies, meeting summary

Challenges in the adoption of regenerative medicine therapies, meeting summary

M Chaddah, S McMahon, J Kusena et al.
13 August 2020
Read
Innovative payments for innovative therapies: adopting value-based models in the regenerative medicines & advanced therapy sector

Innovative payments for innovative therapies: adopting value-based models in the regenerative medicines & advanced therapy sector

10 August 2020
Read

Interview

How should health technology assessment of ATMPs evolve in Europe?

How should health technology assessment of ATMPs evolve in Europe?

Mondher Toumi
2 September 2020
Read
From rare monogenic diseases to Parkinson’s: market access considerations for gene therapy across large and small indications

From rare monogenic diseases to Parkinson’s: market access considerations for gene therapy across large and small indications

Parag Meswani
28 August 2020
Read
HTA evolution in Canada: considerations for cell and gene therapy

HTA evolution in Canada: considerations for cell and gene therapy

Suzanne McGurn
26 August 2020
Read